Targeting the Tumor Locally

Similar documents
Targeting the Tumor Locally

Targeting the Tumor Locally

Targeting the Tumor Locally. April 2018 NASDAQ:ONCS

8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks

OncoSec Provides 2018 Business Outlook

ONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS

Determined to realize a future in which people with cancer live longer and better than ever before

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

KEYNOTE 695: TAVO Phase 2b Melanoma Trial Preliminary Data for SITC November 6, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

Determined to realize a future in which people with cancer live longer and better than ever before

LION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology

Dawson James Conference

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics

Leerink Immuno-Oncology Roundtable Conference

Merck ASCO 2015 Investor Briefing

Combining HS-110 and anti-pd-1 in NSCLC. September 1, 2015

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

Corporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers

Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017

Wells Fargo Healthcare Conference September 6, 2018

Frédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018

IMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

Five Prime Therapeutics, Inc. Corporate Overview

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

Transforming science into medicine

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018

National Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.

Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017

Reimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before

Corporate Presentation

NewLink Genetics Corporation

Idera Pharmaceuticals

Dynavax Corporate Presentation

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer

March Corporate Presentation

Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019

More cancer patients are being treated with immunotherapy, but

Corporate Presentation September Nasdaq: ADXS

NewLink Genetics Corporation

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference

Idera Pharmaceuticals 36 th Annual J.P. Morgan Healthcare Conference Idera Pharmaceuticals

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories

Investor Call. May 19, Nasdaq: IMGN

Leading the Next Wave of Biotech Breakthroughs

Tumor Antigens in the Age of Engineered T cell Therapies

ASCO 2018 Investor Meeting

33 rd Annual J.P. Morgan Healthcare Conference. January 2015

FORWARD II PROGRAM UPDATE

Corporate Overview. February 2018 NASDAQ: CYTR

IMMUNOTHERAPY IMMUNOTHERAPY. 37th Annual JPMorgan Healthcare Conference

The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy

Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.

Corporate Presentation October 2018 Nasdaq: ADXS

Analyst/Investor Call

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO

Pembrolizumab in Metastatic Melanoma

Corporate Presentation March 2016

CORPORATE PRESENTATION

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

Anti-IL-33 (ANB020) Program

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

Third Quarter 2015 Earnings Call. November 9, 2015

Merck Oncology Overview ASCO 2017

JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018

Merck Oncology Overview ASCO 2017

Small-Cap Research. OncoSec Medical (ONCS-NASDAQ) OUTLOOK

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018

ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

The Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018

NASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.

3Q 2016 presentation

RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals

Determined to realize a future in which people with cancer live longer and better than ever before

NewLink Genetics Corporation

Recurrent Ovarian Cancer Phase 1b Results

Arming the patient s immune system to fight cancer

Building a Premier Oncology Biotech

PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective

New Data from Ongoing Melanoma Study and Clinical Development Strategy Update

Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma

Corporate Deck JP Morgan January 2019

Determined to realize a future in which people with cancer live longer and better than ever before

Small-Cap Research. OncoSec Medical (ONCS-NASDAQ) OUTLOOK

Determined to realize a future in which people with cancer live longer and better than ever before

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results

Building a Premier Oncology Biotech

Disclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor

REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

IMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K. ADVAXIS, INC. (Exact Name of Registrant as Specified in Charter)

Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018

PATENCY-1 Top-Line Results

CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS

Corporate Presentation

Transcription:

ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally September 2017 NASDAQ:ONCS

Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations are not descriptions of historical facts regarding OncoSec Medical Incorporated, they should be considered forward-looking statements, as described in the Private Securities Litigation Reform Act of 1995, that reflect management s current beliefs and expectations. You can identify forward-looking statements by words such as anticipate, believe, could, estimate, expect, forecast, goal, hope, hypothesis, intend, may, plan, potential, predict, project, should, strategy, will, would, or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements are not assurances of future performance and include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop and commercialize our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) our and our partners ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process; (v) the size and growth potential of the markets for our product candidates, and our ability to serve those markets; (vi) the rate and degree of acceptance of our product candidates; (vii) our ability to attract and retain key scientific or management personnel; (viii) the anticipated timing of clinical data availability; (ix) the anticipated timing of commercial launch of ImmunoPulse IL-12; (x) our ability to meet our milestones; (xi) our expectations regarding our ability to obtain and maintain intellectual property protection; (xii) the level of our corporate expenditures; (xiii) the assessment of our technology by potential corporate partners; and (xiv) the impact of capital market conditions on us. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward looking statements. These statements are also subject to a number of material risks and uncertainties that are described in OncoSec s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to publicly update any forward-looking statements, except as required by law. OncoSec s investigational drug and device products have not been approved or cleared by the FDA. 2

OncoSec A Near-Term Investment Opportunity ImmunoPulse IL-12 for stage III/IV relapsed/refractory melanoma positioned for accelerated approval ØInitial data mid-2018, seek feedback on accelerated approval ØPotential approval in 2019 via accelerated pathway ØGlobal PISCES trial in melanoma ImmunoPulse IL-12 + checkpoint inhibitor in low-til (cold) at 48% BORR ØOpportunity to expand 1 st line anti-pd-1 response beyond 30-35% ImmunoPulse IL-12 converts checkpoint inhibitor non-responders to responders Ø60-70% of melanoma patients do not respond to checkpoint inhibitors 1 st line 3

~70-90% of Anti-PD-1 Patients Have No Response Significant Patient Population Checkpoint Inhibitors Dramatically Increase Survival in Patients with HOT Tumors Largely Ineffective in COLD Tumors ImmunoPulse IL-12 Tumor Type % Non-Responders Melanoma ~60-80% Triple Negative Breast ~95% 1 Renal Cell Carcinoma ~71% 2 Lung Carcinoma ~79-83% 2 Head and Neck ~68-86% 3,4 Bladder ~85% 5 Gastric ~80% 6 1 ASCO 2017, KEYNOTE-086 Study; 2 Awad and Hammerman, JCO 2015; 3 Ferris et al., N Engl J Med. 2016; 4 Seiwert et al., Lancet Oncl. 2016; 5 Rosenburg et al., Lancet 2016; 6 Muro et al., Lancet Oncl. 2016 4

Interleukin-12 (IL-12): Local Administration Potent and Safe Tavokinogene telsaplasmid encodes IL-12 Potent, well-characterized proinflammatory cytokine Shown to make the tumor micro-environment immunogenic Targets the tumor to signal and traffic immunomodulatory molecules locally while enhancing presentation of tumor antigens to the immune system Safer local delivery with systemic benefits Local immune activation without observed systemic IL-12 tox 5

Plasmid IL-12 + Electroporation Significantly Reduces Tumor Volume vs Plasmid or Protein IL-12 in a Mouse Model of Melanoma 1 5 0 0 1 5 0 0 T u m o r V o l u m e ( m m 3 ) 1 0 0 0 5 0 0 P B S R e c o m b i n a n t I L - 1 2 ( 5 u g ) E m p t y p l a s m i d v e c t o r w i t h E P p I L 1 2 w i t h E P 3 ) T u m o r v o l u m e ( m m 1 0 0 0 5 0 0 N o T r e a t m e n t p I L 1 2 N o E P p I L 1 2 w i t h E P 0 0 0 5 1 0 1 5 0 5 1 0 1 5 D a y s ( p o s t E P ) D a y s ( p o s t E P ) Tavokinogene telseplasmid (plasmid IL-12) injected into B16.F10 melanoma tumor followed by electroporation results in improved tumor regression over IL-12 protein injection alone. Tavokinogene telseplasmid (plasmid IL-12) injected into B16.F10 tumor followed by electroporation results in improved tumor regression tavokinogene telseplasmid without electroporation. Source: OncoSec Data 6

ImmunoPulse IL-12 Phase 2 Monotherapy Data Delivers CRs in Metastatic Melanoma 31% 14% 48% 50% Best Overall Response Complete Response Disease Control Rate Complete Regression in at Least One Lesion Data from our multi-center Phase 2 trial of ImmunoPulse IL-12 demonstrated encouraging single-agent activity in 29 patients with metastatic melanoma Source: Le, Melanoma Bridge 2014 7

ImmunoPulse IL-12 Resensitizes Melanoma Tumors to Anti-PD-1 Converting cold tumors to hot Patients who respond to anti-pd-1 agents will generally have a hot or inflamed tumor, defined by key biomarkers: High expression of PD-L1 on the tumor cell surface High density of tumor-infiltrating lymphocytes (TIL) Presence of biomarkers allows patient selection for response Cold Tumor Hot Tumor Combination strategies have enhanced patient outcomes, clinical benefit and quality of life Source: Algazi, ASCO-SITC 2017 8

// ImmunoPulse IL-12 Converts Cold to Hot in Other Solid Tumor Types Merkel Cell Carcinoma Pre-ImmunoPulse IL-12 LowTIL Post-ImmunoPulse IL-12 High TIL Head & Neck Cancer Post-ImmunoPulse IL-12 High TIL Pre-ImmunoPulse IL-12 LowTIL CD8 Green Foxp3 White FoxP3 Green CD3 - Pink PD-L1 Red CD68 Yellow Sox-10/CK20 Blue PD-L1 Red CD8 Yellow DAPI Blue CD163 - Orange Source: Bhatia, ESMO 2015 Source: Pierce, Eurogin 2016 9

ImmunoPulse IL-12 Phase 2 Combo Data in Low TIL: Best Response in Anti-PD-1 Cold Tumors to Date 48% BORR (RECISTv1.1) with ImmunoPulse IL- 12 + anti-pd-1 in patients unlikely to respond to anti-pd-1 monotherapy ~10% response expected with anti-pd-1 Subset of patients previously treated with checkpoint inhibitors demonstrate 33% BORR Analysis of pre- and post-tumor samples demonstrate conversion of COLD to HOT tumors Data suggest differential immunologic response with responders vs non-responders Source: Algazi, ASCO-SITC 2017 10

PISCES: Clinical Trial Collaboration with Merck & Co. Collaboration Highlights A leading biotechnology company developing DNA-based intratumoral immunotherapies Access to key clinical and development expertise Provide Keytruda throughout the study Joint development committee Global leader in development and commercialization of innovative therapeutics for cancer 11

PISCES: ImmunoPulse IL-12 for Stage III/IV Melanoma Primary outcome may support BLA for accelerated approval in 2019 Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study Single Arm Phase 2/3 study, Simon 2 stage minimax design - 4 responders out of 23 in the first stage à additional 25 patients Primary outcome: BORR based on RECIST v1.1 Secondary outcomes: DOR, PFS and OS Eligible patients: anti-pd-1 non-responders with stage III/IV melanoma - Received 4+ doses of anti-pd-1 - Progressive disease according to RECIST v1.1 - Documented disease progression 24 weeks of the last dose of anti-pd-1 ü Orphan designation ü Fast Track Accelerated pathway Breakthrough status P = Pembrolizumab treatment Up to 48 patients Min 12 sites across US & Australia Enrollment imminent Primary completion by 2H 2018 12

Favorable PISCES Data Could Unlock ~10K Stage III/IV Melanoma Anti-PD-1 Failure Patients (US Only) Combo therapy with checkpoint inhibitors rapidly becoming SOC in cancer Checkpoint products becoming backbone therapy for ~60% or more of all treatable cancers Anti-PD-1 an effective and durable 1 st line Tx for responders ImmunoPulse IL-12 offers a potentially innovative therapeutic intervention for non-responders 1 st Line 2 nd Line 3 rd Line 9.9K 4.0K 1.8K Anti-PD-1 Responders 3.5K 1.4K 0.6K Non-Responders à ~10K Patients 6.4K 2.6K 1.2K R/R: relapsed/refractory Source: DataMonitor Melanoma Forecast & Epidemiology Datapacks, April 2016 13

ImmunoPulse IL-12 Target Product Profile Potentially Superior to Other Agents Under Development Intratumoral Delivery Systemic Delivery Cytokine Delivery of plasmid DNA using proprietary device Fast-track and orphan designation Phase 2 POC data demonstrating safety, efficacy and MOA in combination with KEYTRUDA Targets both intrinsic/extrinsic tumor resistance 48%, n=22 Isolated TIL from patients tumor Fast-track designation Phase 2 data in heavily pre-treated patients in combination with IL-2 Manufacturing plan to be determined 29% ORR, n=13 Non-Cytokine Delivery of TLR-9 using CpGs Early phase 1/2 data in PD-1 experienced patients in combination with KEYTRUDA Lack of MOA data demonstrating combination rationale Targets intrinsic tumor resistance 12%, n=12 Small molecule selective HDAC inhibitor Early phase 1/2 data in PD-1 experienced patients in combination with KEYTRUDA Multiple combination approaches Targets potential epigenetic factors via tumor microenvironment, blockage of MDSCs and Tregs 31% ORR, n=13 14

ImmunoPulse IL-12: the Next Innovation for Oncology Safety Efficacy Response ImmunoPulse IL-12 demonstrated good safety and tolerability; no additive or new AE/SAE in combination trials to date ImmunoPulse IL-12 has shown local and systemic response in PD-I predicted non responders Cold tumors are converted to Hot tumors that respond to anti-pd-1 therapies Safety Improved Anti-PD-1 Response Efficacy 15

OncoSec ImmunoPulse Electroporation Platform ImmunoPulse designed to boost the immune system to recognize and attack tumors DNA plasmids coded to produce immune modulatory proteins are injected directly into tumor Electric pulses increase permeability of cell membrane, facilitating improved uptake of DNA plasmids Product expression cells produce proteins to enhance immunomodulatory molecules to ensure local and systemic immune activation Platform accommodates flexibility and tunability of multiple genes to enable combinations with numerous immune modulators 16

Protecting and Enabling Next Generation Technology to Address Interior Tumors IP and FTO Issued patents on plasmid/ electroporation combination to treat cancer, including melanoma Pending applications on additional methods of use, biomarkers, proprietary devices Building new IP across DNA constructs, next gen devices, new multi-gene combinations, formulations & manufacturing OncoSec GENESIS + TRACE Tissue-Based Real-Time Adaptive Control Electroporation Electrochemical properties of tissues sensed in real time Utilizes mathematical models to maximize delivery Higher and more consistent gene expression across tissues 17

Executing on Key Milestones NEAR-TERM VALUE CREATING MILESTONES Initiate global Ph 2 PISCES trial üearly efficacy in Ph 2 trial üfast Track & Orphan Designation in melanoma SITC/SMR clinical data presentations üexpanded BOD with industry experts 2017 PISCES stage 1 enrollment complete PISCES initial BORR data mid-2018 EOP2 with FDA; seek feedback on AA Multiple scientific/clinical presentations 2018 18

OncoSec A Leader in Intratumoral Cancer Immunotherapies Multiple near-term clinical milestones Addressing important unmet medical need Highly experienced team; enhanced BOD 21M outstanding shares $16.1M as of June 30, 2017 19

Thank you September 2017 Company Contacts 855-662-6732 investors@oncosec.com www.oncosec.com 20

Back-up 21

OncoSec Well-Positioned in the Broader Competitive Landscape Company Phase Therapy Available Data OncoSec Ph 2 (42pts) ImmunoPulse IL-12 + pembro 43% ORR (N=22) Lion Bio Ph 2 (40 pts) LN-144 (TIL) + IL-2 29% ORR (N=13) Syndax Ph 1/2 (158 pts) entinostat (HDAC inhibitor) + pembro 31% ORR (N=13) Idera Ph 1/2 (45 pts) IMO-2125 (IT TLR9 agonist) + ipi 31% ORR (N=9) Dynavax Ph 1/2 SD-101 (IT TLR9 + pembro) 12% ORR (N=12) Biothera Ph 2 (29 pts) Imprime PGG (PAMP) + pembro N/A Nektar Ph 1/2 (N/A) NKTR-214 (peg-il-2) + Nivo N/A Checkmate Ph 1 (60 pts) CMP-001 (IT TLR-9 + pembro) N/A Incyte Ph 1/2 (N/A) Epacadostat (IDO + nivo) N/A Celldex Ph 2 Glembatumumab vedotin (anti-gpnmb + pembro or nivo) N/A Note: All data to-date preliminary and in a population defined as checkpoint therapy experienced 22